echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Anti-high uric acid gingulation domestic market reached 1 billion is still growing rapidly

    Anti-high uric acid gingulation domestic market reached 1 billion is still growing rapidly

    • Last Update: 2021-02-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    According to the Chinese Medical Association Endocrinology Credit Association issued by the "high uric acidemia and gland therapy of Chinese expert consensus" explained that the current Chinese high uric acidemia (HUA) shows a high prevalence, young, male than female, coastal higher than the mainland development trend. High uric acidemia is an independent risk factor for many cardiovascular risk factors and related diseases, and is a direct cause of gaffes.compound new products have been approved by the FDA for listing
    in recent years, the world's newly listed high uric acidemia and glycation treatment drugs are less, with glutast high growth trend performance disorder. Clinically anti-gout drugs were introduced in the 1960s, as well as non-Febuxostat, which was approved by Takeda and Ipsen in 2009, but they are not available to all gout patients and the market is in dire need of new gout drugs.
    December 2015, the FDA approved the listing of Lesinurad, a new drug for high uric acidemia developed by AstraZeneta's Ardea Biosciences, under the trade name Zurampic. Resinard is an oral tablet of selective uric acid re-absorption inhibitor, which works by helping the kidneys excrete uric acid by inhibiting the transport protein function in the kidneys involved in uric acid re-absorption. However, taking Resinard alone does not mean much to gypsum and can only be used in the treatment of high uric acidemia in gyroph patients, and in April 2016, AstraZenecon and Ironwood Pharmaceuticals entered into an exclusive license agreement for Zurampic's U.S. market commercial rights in the face of limited commercial prospects for Zurampic. In addition, its European interests were ceded by Grünenthal.
    August 22, 2017, the FDA approved Ironwood's first gyro-combination drug, Lesinurad and Allopurinol, with the trade name Duzallo. This is the FDA's first anti-gage compound fixed-dose combination drug, driving the pace of the new anti-gage drug market.China's large patient population, high market growth
    the incidence of global gyro is 0.20% to 0.35%, while the incidence of male gyration is 20 times that of women (women with hyperureticemia glands occur mostly after menovascular), so geryro has become a prostate, erectile dysfunction and then a threat to men.
    is an arthritis disorder caused by excess uric acid, a final product metabolized by the serum. In recent years, with the change of diet structure, the excessive intake of sorghum food, resulting in the occurrence of gout shows an increasing trend, it has become the third type of rich disease after high blood sugar, high blood lipids. According to the "China Drug Application and Monitoring" statistics, the incidence of high uric acidemia in China is 10%, about 130 million potential population, gyroph patients about 17 million people, has become China's second largest metabolic diseases, which has aroused widespread concern about the treatment market.The four varieties have obvious advantages and high concentration
    the 2017 Health Insurance Drug Catalog contains a total of 5 varieties of anti-gout drugs, namely non-busta, benzo bromine malone, benzoine alcohol, autumn daffodils and acetaminophen. According to Minetrade data, in 2016 the domestic targeted anti-gantry drug market sales of 729 million yuan. Among them, the treatment of high uric acidemia and gout in public hospitals in key cities amounted to 129 million yuan, an increase of 52.88 percent over the previous year, and was a high growth rate category, with four drug monopolies: non-bustam, benzo bromide malone, benzool and axonol. Among them, non-clothing accounted for 38.28 percent, benzo bromine malone accounted for 31.62 percent, benzodiabolic alcohol accounted for 16 percent, autumn daffodils accounted for 14.10 percent of the share. It is forecast that the sales of targeted anti-gyro-resistant drugs in the domestic market will reach 1 billion yuan in 2017.
    more domestic manufacturers involved in anti-gingring drugs, into key cities public hospitals have 25, TOP5 manufacturers accounted for 86.68 percent of the share. Jiangsu Wanbang came first with 27.32 per cent, Excella with 21.16 per cent and Heilongjiang Australasian 14.69 per cent.Non-busse growth is strong
    Febuxostat is a new drug for the treatment of high uric acid gout, February 13, 2009, Japan's Takeda non-busse he was approved by the U.S. FDA listed, the trade name Uloric, is the first FDA-approved gout drug for nearly 40 years for the treatment of high uric acid. In China as the 2017 health insurance catalog of class B drugs, limited renal insemination and allergic gout allergy gout medication.
    is a new and highly effective selective inhibitor of non-pyrine jaundice oxidase. It reduces uric acid levels in the blood of patients with high uric acidemia geryrosis without inhibiting other enzymes involved in the uric acid path path, making it more safe than allopurinol. In 2013 the domestic research and development of non-cloth he listed. According to the CFDA official website data, the domestic has approved Hangzhou ZhuJiang Heart Pharmaceuticals, Jiangsu Wanbang Biopharmaceuticals shares and Jiangsu Hengrui Pharmaceutical Co., Ltd. 3 non-busted preparations listed. In 2016, non-departmental drugs used in public hospitals in key cities in China were 57.19 million yuan, an increase of 153.28 percent over the previous year. Yu Litong of Wanbang Biopharmaceuticals in Jiangsu Province accounted for 61.74 percent, Rui Yang of Hengrui, Jiangsu Province, accounted for 29.74 percent, and Fengding, of Zhu's heart medicine industry in Hangzhou, accounted for 8.52 percent. Forming the trend of domestic medicine.is highly competitive
    is the main variety in the current domestic gyration market. CFDA released information on December 31, 2014, suggesting that liver damage is more prominent in severe adverse reactions to benzo bromide malone, and that the drug has led to abnormal liver function and elevation of glutamate transaminase, glutamate transaminase and alkaline phosphatase, thus casting a shadow over the market prospects of benzo bromine malone.
    2000 benzo bromine Malone was listed in China, and the imported drug currently on the market is Narcaricin Mite, a benzo bromine Malone tablet from Sano Arzneimittelfabrik GmbH in Germany. Domestic benzo bromine Malone oral preparations are Changzhou Kangpu Pharmaceuticals, Kunshan Dragon Light Reddy Pharmaceuticals, Chengdu Huasan Group shares and Yichang Dong Sunshine Yangtze River Pharmaceuticals production.
    2016, the amount of phenyl bromine malone drug use in key urban hospitals in China was 47.24 million yuan, an increase of 17.05 percent over the previous year. Imported drugs accounted for 57.90 per cent and domestic medicines for 42.10 per cent. Among them, Kunming dragon lamp Reddy's step Lixian accounted for 28.31 percent, Yichang East Sunshine Yangtze River Pharmaceuticals' Er Tongshu accounted for 8.56 percent, Changzhou Kangpu Pharmaceuticals' Yuno accounted for 4.54 percent, Chengdu Tai and Health Huasan's Meisheng accounted for 0.68 percent.The steady growth of allopurinol
    allopurinol is the drug of choice for the treatment of chronic gyration, and is also the main clinically effective drug to reduce uric acid production and reduce blood uric acid levels to treat primary gingulation. Allopurinol is a drug approved for market use by the FDA for many years, and so far 17 companies in China have produced allopurinol oral tablets. In 2016, the amount of allopurinol used in public hospitals in key cities in China was 23.93 million yuan, an increase of 14.28% over the previous year. TOP5 is 79.33 percent in Heilongjiang, 8.94 percent in the WORLD Trade Organization, 7.29 percent in Shanghai, 3.83 percent in Qingyang, Chongqing, and 0.25 percent in Guangzhou.Qiu daffodils ups and downs
    autumn daffodils is an effective drug for the treatment of acute gout, can effectively relieve the pain of gout attacks, especially for acute gout arthritis has a specific role, anti-inflammatory treatment can effectively prevent the re-acute onset of gout. However, 50% to 80% of patients taking autumn daffodils before the gout attack can be alleviated has appeared gastrointestinal adverse reactions, thus affecting the growth of the autumn daffodils market, on the other hand, autumn daffodils raw materials in addition to India imports, only Kun Pharmaceutical Group and Xishuangbna Pharmaceutical production.
    2016, the amount of medicine used in public hospitals in key cities in China was 900,000 yuan, an increase of 33.98 percent over the previous year. TOP5 is 49.01 percent for Kunming Pharmaceuticals, 21.47 percent for Yunnan Plant Pharmaceuticals, 9.58 percent for Xishuangdana Pharmaceuticals, 7.21 percent for Jingde Pharmaceuticals (Taiwan), 5.56 percent for Guangdong Petty, and 7.17 percent for other companies. (Mi Net)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.